Lei Xia

Dr. Lei Xia

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
Purpose: Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently, enfortumab vedotin (EV) was approved by the FDA as the first nectin-4 targeting antibody–drug conjugate for treating advanced urothelial carcinoma (UC). A PET imaging method to noninvasively quantify nectin-4 expression level would potentially help to select patients most likely to respond to EV and predict the response. Experimental Design: In this study, we designed a bicyclic peptide-based nectin-4 targeting radiotracer 68Ga-N188. Initially, we performed preclinical evaluations of 68Ga-N188 in UC cell lines and xenograft mouse models. Next, we performed the translational study in healthy volunteers and a pilot cohort of patients with advanced UC on uEXPLORER total-body PET/CT. Results: In the preclinical study, 68Ga-N188 showed high affinity to nectin-4, specific uptake in a nectin-4(+) xenograft mouse model, and suitable pharmacokinetic and safety profiles. In the translational study, 2 healthy volunteers and 14 patients with advanced UC were enrolled. The pharmacokinetic profile was determined for 68Ga-N188, and the nectin-4 relative expression level in different organs was quantitatively imaged. Conclusions: A clear correlation between PET SUV value and nectin-4 expression was observed, supporting the application of 68Ga-N188 PET as a companion diagnostic tool for optimizing treatments that target nectin-4. See related commentary by Jiang et al., p. 3259

4 July 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
LXLei Xia
Lei Xia
XGXiaoyi Guo
Xiaoyi Guo
TLTeli Liu
Teli Liu
XXXiaoxia Xu
Xiaoxia Xu
JJJinquan Jiang
Jinquan Jiang
ZYZhi Yang
Zhi Yang
Naturally active melanin nanoparticles (124I, Mn) OCT-PEG-MNP for multimodal imaging of human small-cell lung cancer.

23 January 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LXLei Xia
Lei Xia
YWYan Wu
Yan Wu
YRYanan Ren
Yanan Ren
ZWZhen Wang
Zhen Wang
NZNina Zhou
Nina Zhou
ZYZhi Yang
Zhi Yang
BACKGROUND: B7H3, also known as CD276, is notably overexpressed in various malignant tumor cells in humans, with extremely high expression rates. The development of a radiotracer that targets B7H3 may provide a universal tumor-specific imaging agent and allow the noninvasive assessment of the whole-body distribution of B7H3-expressing lesions. METHODS: We enhanced and optimized the structure of an affibody (ABY) that targets B7H3 to create the radiolabeled radiotracer [ 68 Ga]Ga-B7H3-BCH, and then, we conducted both foundational experiments and clinical translational studies. RESULTS: [ 68 Ga]Ga-B7H3-BCH exhibited high affinity (equilibrium dissociation constant [K D ] = 4.5 nM), and it was taken up in large amounts by B7H3-transfected cells (A549 CD276 and H1975 CD276 cells); these phenomena were inhibited by unlabeled precursors. Moreover, PET imaging of multiple xenograft models revealed extensive [ 68 Ga]Ga-B7H3-BCH uptake by tumors. In a clinical study including 20 patients with malignant tumors, the [ 68 Ga]Ga-B7H3-BCH signal aggregated in both primary and metastatic lesions, surpassing fluorine-18 fluorodeoxyglucose ( 18 F-FDG) in overall diagnostic efficacy for tumors (85.0% vs. 81.7%), including differentiated hepatocellular and metastatic gastric cancers. A strong correlation between B7H3 expression and [ 68 Ga]Ga-B7H3-BCH uptake in tumors was observed, and B7H3 expression was detected with 84.38% sensitivity and 100% specificity when a maximum standardized uptake value (SUVmax) of 3.85 was set as the cutoff value. Additionally, B7H3-specific PET imaging is expected to predict B7H3 expression levels in tumor cells, intratumoral stroma, and peritumoral tissues. CONCLUSION: In summary, [ 68 Ga]Ga-B7H3-BCH has potential for the noninvasive identification of B7H3 expression in systemic lesions in patients with malignant tumors. This agent has prospects for improving pretreatment evaluation, predicting therapeutic responses, and monitoring resistance to therapy in patients with malignancies. TRIAL REGISTRATION: ClinicalTrials.gov NCT06454955. FUNDING: This research was financially supported by the Natural Science Foundation of Beijing Municipality (no. 7242266), the National Natural Science Foundation of China (no. 82202201), and the Young Elite Scientists Sponsorship Program by China Association for Science and Technology (CAST) (no. YESS20220230).

13 June 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LXLei Xia
Lei Xia
CHChengxue He
Chengxue He
YGYanhui Guo
Yanhui Guo
XMXiangxi Meng
Xiangxi Meng
TLTeli Liu
Teli Liu
ZYZhi Yang
Zhi Yang

24 December 2024 in Materials Today Bio
Verified
Journal Article
Open access
LWLi Wen
Li Wen
CHChengxue He
Chengxue He
YGYanhui Guo
Yanhui Guo
NZNina Zhou
Nina Zhou
XMXiangxi Meng
Xiangxi Meng
LXLei Xia
Lei Xia
Fibroblast activating protein (FAP) is up-regulated in cancer-associated fibroblasts (CAFs) of more than 90 % of tumor microenvironment and also highly expressed on the surface of multiple tumor cells like glioblastoma, which can be used as a specific target for tumor diagnosis and treatment. At present, small-molecule radiotracer targeting FAP with high specificity exhibit limited functionality, which hinders the integration of theranostics as well as multifunctionality. In this work, we have engineered a multifunctional nanoplatform utilizing organic melanin nanoparticles that specifically targets FAP, facilitating both multimodal imaging and synergistic therapeutic applications. This nanoplatform can perform positron emission tomography (PET), magnetic resonance imaging (MRI) and photoacoustic imaging (PAI) with strong near infrared absorption and metal chelating ability, achieving efficiently targeting accumulation and display long retention in the tumor region. Meanwhile, 131I-labeled nanoplatform for targeted radioisotope therapy (TRT) and photothermal therapy (PTT) were significantly suppressed tumor growth in glioblastoma xenograft models without obvious side effects. These results demonstrated that this novel nanoparticles-based theranostics nanoplatform can effectively enhance multimodal imaging and targeted radionuclide-photothermal synergistic therapy for solid tumors with FAP expression.

1 November 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LXLei Xia
Lei Xia
LWLi Wen
Li Wen
XMXiangxi Meng
Xiangxi Meng
NZNina Zhou
Nina Zhou
XGXiaoyi Guo
Xiaoyi Guo
ZYZhi Yang
Zhi Yang
Background: In recent years, nuclear medicine imaging and therapy for prostate cancer have radically changed through the introduction of radiolabeled prostate-specific membrane antigen (PSMA)-binding peptides. However, these small molecular probes have some inherent limitations, including high nephrotoxicity and short circulation time, which limits their utility in biological systems. Methods and Results: In this study, organic melanin nanoparticles were used to directly label the long half-life radionuclide 124I (t1/2=100.8 h), and PSMA small molecular groups were efficiently bonded on the surface of nanoparticles to construct the PSMA-targeted long-retention nanoprobe 124I-PPMN, which has the potential to increase tumor uptake and prolong residence time. The results showed that the nanoprobe could substantially aggregate in the tumors of prostate cancer xenograft mice and was visible for more than 72 h. Positron Emission Computed Tomography (PET) imaging showed that the nanoprobe could be used for precise imaging of prostate cancer with high expression of PSMA. In addition, organic melanin nanoparticles labeled with an elemental radionuclide achieved a stable, metal-free structure. Cell experiments and mouse toxicity experiments indicated that the nanoprobe has high safety. Conclusion: The new nanoprobe constructed in this study has high specificity and biocompatibility. In the future, combined with the multifunctional potential of melanin nanoparticles, this nanoprobe is expected to be used in the integrated theranostics of prostate cancer.